Symposium on new progress in clinical research of rituximab

- NanJing Railway Station

Seminar on the new progress of clinical research on the treatment of "new progress in the clinical research of the Pearl of the Pearl in August 30, 2012" in Nanjing.

3 pm, 100 people in the venue All seats are occupied. President Qin Shukui's speech, the president opened the prelude to the meeting ebullience. First Cuban Academy of Sciences Rolando Professor report, nimotuzumab development history, mechanism of action and global clinical research progress are introduced, nimotuzumab as a new generation of anti EGFR monoclonal antibody, on behalf of the most cutting-edge monoclonal antibody technology, mechanism also don't in the similar products, the professor Rolando with straightaway language to explain the basic theory of obscure and received high praise from the experts in the field, experts in the field with a positive question, from the theoretical basis to clinical research, Rolando answer the audience on many aspects of nimotuzumab doubts. Qin long also repeatedly praised the school trip. The second report of Shanghai Huashan Hospital pancreatic surgery Professor de Liang Fu, pancreatic cancer as the incidence rate is low, but very high mortality of the disease has been of concern to the majority of doctors of cancer, Professor Fu and everyone shared the status of pancreatic cancer, and nimotuzumab pancreatic cancer clinical research progress, for the treatment of pancreatic cancer opened a new train of thought; and in 2008, the European Union approved nimotuzumab as orphan drug combined with gemcitabine in phase III clinical trials and is currently underway. Then, Professor Shu Yongqian and Professor Wang Buhai from the people's Hospital of Northern Jiangsu Province also share with you the experience of targeted therapy in the Department of internal medicine and radiotherapy and chemotherapy treatment of diseases.

Through the academic exchange conference held, the majority of doctors to share the Nimotuzumab in the treatment of cancer research and application. Dean finally qinshukui concluded: "Baitai biological in the biopharmaceutical industry made great efforts, and hope to through the platform for academic exchanges and to clinical work can help, nimotuzumab can get reasonable application, and the majority of patients bring more benefit."